Thatcher Heumann
@HeumannThatcher
Followers
178
Following
394
Media
4
Statuses
81
Joined January 2020
1) We recently identified a serum tumor biomarker of fibrolamellar carcinoma, called procalcitonin, with @Zucmanrossi and @MarkYarchoan that you can find in
medrxiv.org
Introduction Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers (alpha-fetoprotein (AFP) and CA19-9). An...
1
5
4
1/ Excited to share our newest study in Nat Med on a vaccine targeting the recurrent fusion DNAJ-PKAc in #fibrolamellar carcinoma (FLC), a rare liver cancer affecting kids & young adults Full paper: https://t.co/ZjKtNEcAup
@PGTimmune & @marinabaretti & @FibroFoundation
5
11
73
Clinically relevant for hepatobiliary oncologists: ➡️ Procalcitonin is a circulating tumor marker for #fibrolamellar carcinoma (like AFP in HCC & CA19-9 in CCA). Led by @NaultJc and @rossi_zucman. W/ @marinabaretti @_WaqarArif @neumannethan98 Preprint: https://t.co/44pkiWfq63
1
27
50
LEAP 012 Update (News from Industry) Source MERCK Merck and Eisai announced results from the Phase 3 LEAP-012 trial evaluating the combination of pembrolizumab and lenvatinibwith transarterial chemoembolization (TACE) in patients with unresectable, non-metastatic hepatocellular
0
5
10
Representing @VUMCDiscoveries in Boston at #Targets25. Characterizing Pin1 and GDF15 mRNA expression in a large real world cohort of biliary tract cancer. Grateful for the collaboration with Dr. Justin Lo and @TempusAI. @jordanberlin5 @CathyEngMD @KristenCiombor @curecc
1
4
15
🏥Nab-paclitaxel plus bevacizumab for metastatic extrapulmonary NEC @eClinicalMed ➡️Mainly GI primary ➡️Previosly treated (%50 at least 2line) ✅mOS: 12.8 mo ✅mPFS: 5.3 mo ✅ORR: 55% 👉 https://t.co/YRf5tGfO67
#cancer #oncology #MedX #nec @OncoAlert @OncoThor @UGrewalMD
3
14
43
🚨 PHERFLOT trial just set a new bar for localized HER2⁺ gastro-esophageal adenocarcinoma! 💊 Regimen: Peri-op FLOT + trastuzumab + pembrolizumab (x4 pre-op + x4 post-op + maintenance up to 1 yr) 👩⚕️ 31 pts (Germany, NCT05504720) 🔹 Median age 65 🔹 81 % HER2 IHC 3⁺ 🔹 67 % ≥
1
40
94
#ESMO25 surprise: PRODIGE 81: ATEZO + BEV ± IPI (1 mg/kg) n=226 pts ➡️Adding IPI showed no benefit, ORR (30% vs 27.4%) Confusing b/c IPI at 1mg/kg is active in HCC (ORR for NIVO/IPI 1 is ~2x NIVO mono) & NIVO/IPI is active post ATEZO + BEV --> Doublets here to stay a while☹️
0
5
13
Comparison of outcomes in clinical trials of locally advanced dMMR colon cancer: FOxTROT and NICHE-2 #ESMO25 #ESMOAmbassadors 👉 patient based comparison 👉 Final coffin nail for CTx 👉 Can we omit surgery next? 🧐 Amazing efficacy for ICI in MSI CRC @myesmo
5
33
74
🫁 #ESMO25 – BEAMION LUNG-1 w/ @DrSanjayPopat: first-line Zongertinib in HER2-mut NSCLC! 🎯ORR 77%, DCR 96% 💥Durable responses (6-mo DoR 80%, PFS 79%) 👍🏼 Manageable safety, no grade 4/5 AEs Promising data that gives HER2-mut NSCLC (quite literally) a new breath of LUNG ✨
1
15
37
☢️Conversion therapy for unresectable pancreatic cancer CONKO-007 @JCO_ASCO ➡️3mo induction ChT (84% Folfirinox) ➡️Then randomize: same ChT vs CRT 🚨Progression after induction: 32.1% ❌R0 rate in ITT pop.: 18% vs 25%, p=0.113 ❌Similar surgery rate ✅Among operated ones,
1
22
52
Check out our new paper in Hepatology on how myeloid cells limit #immunotherapy in preclinical #cholangiocarcinoma models! Disease site matters! Collaborative effort with @Chrystal_Paulos and many others @WinshipAtEmory @KimmelCancerCtr @VanderbiltU
https://t.co/Ug08v6zKlo
pubmed.ncbi.nlm.nih.gov
These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant...
2
10
24
#ASCO25 @ASCO 4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍 👇my top picks for key abstracts to watch for🌟 ➡️Two GI plenary sessions🏅 MATTERHORN #STCsm @YJanjigianMD ATOMIC #dMMR #CRCsm @FASinicropeMD ➡️Clinical Science Symposium
2
38
113
🟡Is Claudin 18.2 expressed in biliary tract cancers? @ESMO_Open ✅29.5% express gallbladder: 62.5%, extrahepatic: 53.4%, intrahepatic: 12.9% ✅Positivity (if ≥75% of tumor cells): 5.5% gallbladder: 15.6%, extrahepatic: 8.6%, intrahepatic: 2% ❓A potential target for
1
28
88
Original Article Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study Moeckli et al. #LiverX
https://t.co/CMp2tJZfzv
0
32
66
Expansive review of IO across solid tumours in collaboration with Dr. Wang and my old colleague and friend Dr. Lei Zheng, now cancer centre director at UT! Clinical development of immuno-oncology therapeutics https://t.co/A6LoUpRpfK
1
11
50
🔥off the press Precision surgery for hepatocellular carcinoma @LancetGastroHep
https://t.co/ALCbp8ppXl 👉the field is moving to precision medicine 👉Our thoughts on current strategies & future opportunities > team work is key for personalized therapy @myESMO @EASLedu @ILCAnews
2
26
74
Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection: https://t.co/csoeKq22HU Authored by @jamesyuhemonc
https://t.co/2SC5BxydSX
#gicsm
ascopubs.org
PURPOSEThis study aimed to assess (1) the prognostic value of circulating tumor DNA (ctDNA) and (2) the ability of ctDNA to detect recurrence compared with standard surveillance in curatively...
0
3
6
Check out our recent review of contemporary & novel IO in HCC! Fantastic effort by VUMC resident and my mentee @ShabnamEghbali. Link below. @CathyEngMD @VUMCMedicineRes @VUMC_Cancer @drlauragoff
https://t.co/dujm3tXda7
mdpi.com
Simple SummaryIn recent years, there has been a paradigm shift in first-line treatment for unresectable hepatocellular carcinoma (HCC) from multitargeted tyrosine kinase inhibitors to immune checkp...
0
1
3